RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
TUCCI M
Collezione AOU San Luigi di Orbassano
Items : 99
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12.
2024
ASL Asti
AOU San Luigi di Orbassano
AO Ordine Mauriziano
Tucci M; Scagliotti GV; Di Maio M; Palesandro E; Poletto S; Calabrese M; Saporita I; Crespi V; Farinea G; Di Stefano RF; Gallina A; Fossati N; Zilli T; Delcuratolo MD; Gillessen S; Turco F; Vogl UM; Buttigliero C;
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma. in Journal of clinical medicine / J Clin Med. 2024 Jan 5;13(2):307. doi: 10.3390/jcm13020307.
2024
ASL Asti
AOU San Luigi di Orbassano
Buttigliero C; Carfì FM; Tucci M; Calabrese M; Saporita I; Pisano C; Turco F; Delcuratolo MD; Di Stefano RF; Samuelly A;
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. in Cells / Cells. 2024 Aug 22;13(16):1396. doi: 10.3390/cells13161396.
2024
ASL Asti
AOU San Luigi di Orbassano
Tucci M; Di Stefano FR; Audisio M; Turco F; Delcuratolo MD; Poletto S; Saporita I; Carfì F; Calabrese M; Farinea G; Buttigliero C;
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Città di Torino
AO Cuneo
ASL Asti
ASL Cuneo 2
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Filippi R; Brusa F; Prati V; Vana F; Mennitto A; Maio MD; Buttigliero C; Vignani F; Dionisio R; Icardi M; Guglielmini P; Buosi R; Stevani I; Vormola R; Numico G; Depetris I; Comandone A; Gennari A; Airoldi M; Rossi M; Vellani G; Ortega C; Ruatta F; Tucci M; Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; et alii...
Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2023 Jan;181:103881. doi: 10.1016/j.critrevonc.2022.103881. Epub 2022 Nov 24
2023
AO Ordine Mauriziano
ASL Asti
AOU San Luigi di Orbassano
Scagliotti GV; Buttigliero C; Di Maio M; Audisio A; Brusa F; Ungaro A; Audisio M; Samuelly A; Turco F; Di Stefano RF; Tucci M; Delcuratolo MD;
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer. in International journal of molecular sciences / Int J Mol Sci. 2023 Dec 20;25(1):78. doi: 10.3390/ijms25010078.
2023
ASL Asti
AOU San Luigi di Orbassano
Farinea G; Poletto S; Carfì FM; Di Stefano RF; Vogl UM; Castro E; Gillessen S; Turco F; Saporita I; Calabrese M; Tucci M; Buttigliero C;
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis. in Tumori / Tumori. 2023 Apr;109(2):233-243. doi: 10.1177/03008916221077144. Epub 2022 Mar 31.
2023
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Di Maio M; Scagliotti GV; Ungaro A; Parlagreco E; Audisio A; Audisio M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Tucci M; Turco F;
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11
2022
ASL Asti
ASL Torino 4
ASL Cuneo 1
ASL Cuneo 2
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Scagliotti GV; Di Maio M; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Parlagreco E; Di Stefano RF; Audisio M; Tucci M;
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. in Cells / Cells. 2022 Jan 21;11(3):357. doi: 10.3390/cells11030357.
2022
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano
Tucci M; Di Prima L; Turco F; Di Stefano RF; Ungaro A; Audisio M; Parlagreco E; Delcuratolo MD; Audisio A; Buttigliero C;
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside. in Cells / Cells. 2022 Feb 25;11(5):803. doi: 10.3390/cells11050803.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Delcuratolo MD; Ungaro A; Buttigliero C; Di Maio M; Audisio A; Di Prima L; Turco F; Scagliotti GV; Pisano C; Tucci M;
Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.
2022
ASL Asti
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Pisano C; DI Maio M; Tucci M; Scagliotti GV; Samuelly A; DI Stefano RF; Turco F; Bungaro M; Parente A; Buttigliero C; Angusti T;
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
ASL Cuneo 2
ASL Torino 4
ASL Cuneo 1
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Turco F; Ungaro A; Audisio M; Scagliotti GV; Di Maio M; Delcuratolo MD; Audisio A; Ortega C; Pisano C; Buttigliero C; Di Stefano RF; Tucci M;
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Cortesi E; Spada M; Salgarello M; Pignata S; Borsatti E; Zichi C; Filice A; Murabito A; Fanti S; Biasco E; Palermo A; Alongi P; Alongi F; Bortolus R; Facchini G; Baldari S; Tucci M; Pinto C; Monari F; Sbrana A; Costa RP; Vincentis G; Caffo O; Frantellizzi V;
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. in Endocrine-related cancer / Endocr Relat Cancer. 2021 Jun 2;28(7):R207-R216. doi: 10.1530/ERC-20-0457.
2021
ASL Asti
ASL Vercelli
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Di Maio M; Scagliotti GV; Pisano C; Audisio M; Samuelly A; Bungaro M; Tucci M; Di Stefano RF; Turco F;
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without (223)Ra. in Cancer biotherapy & radiopharmaceuticals / Cancer Biother Radiopharm. 2021 Jun;36(5):391-396. doi: 10.1089/cbr.2020.4442. Epub 2021 Mar 25.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
De Vincentis G; Cortesi E; Lo Re G; De Giorgi U; Spada M; Salgarello M; Borsatti E; Zichi C; Pignata S; Morabito A; Masini C; Sbrana A; Fanti S; Donner D; Alongi P; Bortolus R; Alongi F; Facchini G; Baldari S; Costa RP; Pinto C; Tucci M; Galli L; Monari F; Caffo O; Frantellizzi V;
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2021 Jan;157:103185. doi: 10.1016/j.critrevonc.2020.103185. Epub 2020 Nov 27
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
AO Ordine Mauriziano
Buttigliero C; Di Maio M; Scagliotti GV; Di Stefano RF; Turco F; Tucci M; Pisano C;
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.
2021
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
ASL Torino 4
AO Ordine Mauriziano
Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Vignani F; Bungaro M; Samuelly A; Turco F; DI Stefano RF; Tucci M; Pisano C;
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. in Tumori / Tumori. 2021 Dec;107(6):NP149-NP154. doi: 10.1177/03008916211059230. Epub 2021 Nov 11.
2021
ASL Asti
AOU San Luigi di Orbassano
Buttigliero C; Scagliotti GV; Bollito E; Bungaro M; Di Stefano RF; Samuelly A; Tucci M; Turco F;
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):870-872. doi: 10.23736/S2724-6051.21.04817-5.
2021
ASL Asti
ASL Torino 4
AOU San Luigi di Orbassano
Tucci M; Turco F; Buttigliero C;
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). in Clinical Medicine Insights. Oncology / Clin Med Insights Oncol. 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. eCollectio
2021
AOU San Luigi di Orbassano
Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A;
Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. in Cancers / Cancers (Basel). 2020 Sep 9;12(9):2568. doi: 10.3390/cancers12092568.
2020
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano
ASL Vercelli
Tucci M; Di Maio M; Necchi A; Gamba T; Buttigliero C; Vignani F; Marandino L;
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. in JAMA network open / JAMA Netw Open. 2020 Oct 1;3(10):e2021692. doi: 10.1001/jamanetworkopen.2020.21692.
2020
AOU San Luigi di Orbassano
Zürrer-Härdi U; Le ML; Bergman AM; Karalis K; Castro E; Tucci M; Lavaud P; Morales-Barrera R; Beer TM; Hansen AR; De Giorgi U; Bianchini D; Chi KN; Di Lorenzo G; Yip SM; Ledet E; Sartor O; Tsao CK; Oh WK; Vargas Pivato de Almeida D; Cotait Maluf F; Conteduca V; Beltran H; Kuppen MCP; Mehra N; Martinez Chanza N; Sweeney C; Higano C; Omlin A; et alii...
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.
2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Zucali P; Tucci M; Verri E; Procopio G; Mucciarini C; Mosca A; Massari F; Fratino L; Masini C; Fornarini G; Ermacora P; Donini M; Buti S; Ceresoli GL; Bortolus R; Berruti A; Baldessari C; Buttigliero C; Zagonel V; Caffo O;
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2633-2638. doi: 10.1007/s00259-020-04796-w. Epub 2020 Ap
2020
AOU San Luigi di Orbassano
Borsatti E; Rossetti S; Filice A; Pignata S; Biasco E; Fanti S; Zichi C; Alongi P; Agostini S; Facchini G; Bortolus R; Masini C; Baldari S; Monari F; Galli L; Tucci M; Frantellizzi V; Caffo O; Spada M; Cortesi E; De Vincentis G;
Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2020 Feb;18(1):69-76.e4. doi: 10.1016/j.clgc.2019.09.010. Epub 2019 Sep 27.
2020
AOU San Luigi di Orbassano
Pappagallo G; Galli L; Gelderblom H; Tucci M; De Giorgi U; Zagonel V; Sella A; Bournakis E; Yu EY; Schmid S; Thomsen FB; Bergman A; Bianchini D; Wissing M; Caffo O; Bria E; Sperduti I; Oudard S;
Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2020 Dec;72(6):737-745. doi: 10.23736/S0393-2249.20.03708-X. Epub 2020 Apr 10.
2020
AOU San Luigi di Orbassano
AO Ordine Mauriziano
Di Maio M; Numico G; Scagliotti GV; Guglielmini P; Lacidogna G; Turco F; Di Stefano RF; Pisano C; Buttigliero C; Tucci M; Sonetto C; Vignani F;
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2020 Aug;152:102994. doi: 10.1016/j.critrevonc.2020.102994. Epub 2020 May 24
2020
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
AO Ordine Mauriziano
Di Maio M; Tucci M; Scagliotti GV; Vignani F; Turco F; Tabbò F; Pisano C; Di Stefano RF; Buttigliero C; Leone G;
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223) in Journal of Clinical Oncology
2020
ASL Asti
AOU San Luigi di Orbassano
Caffo O; Frantellizzi V; Tucci M; Galli L; Monari F; Baldari S; Masini C; Bortolus R; Facchini G; Alongi P; Zichi C; Biasco E; Fanti S; Pignata S; Filice A; Borsatti E; Rossetti S; Spada M; Cortesi E; De Vincentis G;
Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. in Cancer drug resistance (Alhambra, Calif.) / Cancer Drug Resist. 2020 Sep 12;3(4):726-741. doi: 10.20517/cdr.2020.42. eCollection 2020.
2020
ASL Asti
AOU San Luigi di Orbassano
Tucci M; Buttigliero C; Bungaro M;
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Oct;17(5):332-347.e2. doi: 10.1016/j.clgc.2019.07.007. Epub 2019 Jul 20
2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Novello S; Aglietta M; Tucci M; Buttigliero C; Sonetto C; La Salvia A; Muratori L; Leone G; Trevisi E; Mariniello A; Ghisoni E; Di Stefano RF; Pignataro D; Reale ML; Lombardi P; Zichi C; De Luca E; Marandino L; Scagliotti GV; Perrone F; Di Maio M;
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. in Cancer treatment reviews / Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7.
2019
AOU San Luigi di Orbassano
Scagliotti GV; Veccia A; Rossetti S; Rizzo M; Maines F; Kinspergher S; Di Maio M; Cavaliere C; D'aniello C; Buttigliero C; Tucci M; Caffo O; Facchini G;
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents. in Endocrine / Endocrine. 2019 Jun;64(3):724-726. doi: 10.1007/s12020-019-01947-4. Epub 2019 May 7.
2019
ASL Asti
AOU San Luigi di Orbassano
ASL Vercelli
Berruti A; Vittorio Scagliotti G; Sigala S; Buttigliero C; Bedussi F; Dalla Volta A; Pia A; Ferrari L; Tucci M; Roca E;
68Ga-PSMA Uptake in Fibrous Dysplasia. in Clinical nuclear medicine / Clin Nucl Med. 2019 Jun;44(6):e396-e397. doi: 10.1097/RLU.0000000000002546.
2019
AOU San Luigi di Orbassano
Giardino R; Buttigliero C; Tucci M; Reale ML; Poti C;
Prostate cancer management at an Italian tertiary referral center: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2019 Dec;71(6):576-582. doi: 10.23736/S0393-2249.19.03231-4. Epub 2019 Sep 4.
2019
AOU San Luigi di Orbassano
Buttigliero C; Passera R; Solitro F; Bollito E; Allis S; Poggio M; Tucci M; Fiori C; De Luca S; Porpiglia F;
Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Aug;17(4):291-298. doi: 10.1016/j.clgc.2019.05.002. Epub 2019 May 13.
2019
AOU San Luigi di Orbassano
Prisciandaro M; Tucci M; Galli L; Buti S; Facchini G; Cartenì G; Fornarini G; Cortesi E; Bregni M; Verzoni E; Ratta R; Peverelli G; Raimondi A; Procopio G;
Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016 in Journal of Clinical Oncology
2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; ButtIgliero C; Tucci M; Aglietta M; Scagliotti GV; Perrone F; Di Maio M;
Seuencing chemotherapy and immune checkpoint inhibitors C in metastatic urothelial carcinoma UC: Meet-Uro1 study in Journal of Clinical Oncology
2019
AOU San Luigi di Orbassano
Bandini M; Farè E; Raggi D; De Giorgi U; Banna GL; Basso U; Losanno T; Bersanelli M; Buti S; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Ficorella C; Caffo O; Naglieri E; Pederzoli F; Pignata S; Necchi A;
Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. in Cancer treatment reviews / Cancer Treat Rev. 2018 Sep;69:215-223. doi: 10.1016/j.ctrv.2018.07.010. Epub 2018 Jul 20.
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Di Maio M; Scagliotti GV; Ricardi U; Ruo Redda MG; Di Stefano RF; Leone G; Zichi C; Tucci M; Allis S; Buttigliero C; Filippi AR;
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2018 Sep;129:124-132. doi: 10.1016/j.critrevonc.2018.07.004. Epub 2018 Jul 1
2018
AOU San Luigi di Orbassano
Di Nunno V; De Luca E; Buttigliero C; Tucci M; Vignani F; Gatto L; Zichi C; Ardizzoni A; Di Maio M; Massari F;
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. in Cancer treatment reviews / Cancer Treat Rev. 2018 Nov;70:67-74. doi: 10.1016/j.ctrv.2018.08.005. Epub 2018 Aug 11.
2018
AOU San Luigi di Orbassano
Mosillo C; Iacovelli R; Ciccarese C; Fantinel E; Bimbatti D; Brunelli M; Bisogno I; Kinspergher S; Buttigliero C; Tucci M; Caffo O; Tortora G;
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.
2018
ASL Cuneo 2
AOU San Luigi di Orbassano
Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E; Fornarini G; et alii...
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report. in BMC cancer / BMC Cancer. 2018 Apr 26;18(1):470. doi: 10.1186/s12885-018-4395-5.
2018
AOU San Luigi di Orbassano
Zichi C; Tampellini M; Tucci M; Sonetto C; Baratelli C; Brizzi MP; Scagliotti GV;
Hormonal treatment and quality of life of prostate cancer patients: new evidence. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2018 Apr;70(2):144-151. doi: 10.23736/S0393-2249.17.03066-1. Epub 2017 Dec 14.
2018
AOU San Luigi di Orbassano
Tucci M; Leone G; Buttigliero C; Zichi C; DI Stefano RF; Pignataro D; Vignani F; Scagliotti GV; DI Maio M;
Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. in OncoTargets and therapy / Onco Targets Ther. 2018 Oct 24;11:7353-7368. doi: 10.2147/OTT.S153764. eCollection 2018.
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M;
Survival outcomes from a cumulative analysis from worldwide observational studies on sequential use of new agents (NAs) in metastatic castration-resistant prostate cancer (mCRPC) (CASTOR study) in Journal of Clinical Oncology
2018
AOU San Luigi di Orbassano
Caffo O; Wissing M; Bianchini D; Bergman AM; Thomsen FB; Schmid S; Yu EY; Bournakis E; Sella A; Basso U; De Giorgi U; Tucci M; Gelderblom H; Galli L; Sperduti I; Oudard S;
Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (PTS) in the daily practice: Preliminary results from a retrospective study in Italian centers in Journal of Clinical Oncology
2018
AOU San Luigi di Orbassano
Caffo O; Frantellizzi V; Monari LGF; Facchini G; Baldari S; Tucci M; Bortolus FAR; Agostini S; Biasco E; Fanti S; Rossetti S; Pignata S; Zichi C; Salgarello M; Borsatti E; Sbrana ECA; Vincentis GD;
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2017 Sep 6:S1558-7673(17)30275-6. doi: 10.1016/j.clgc.2017.08.020.
2017
AOU San Luigi di Orbassano
Heinrich D; Bektic J; Bergman AM; Caffo O; Cathomas R; Chi KN; Daugaard G; Keizman D; Kindblom J; Kramer G; Olmos D; Omlin A; Sridhar SS; Tucci M; van Oort I; Nilsson S;
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. in Lancet (London, England) / Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.
2017
AOU San Luigi di Orbassano
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; et alii...
223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma. in Clinical nuclear medicine / Clin Nucl Med. 2017 May;42(5):391-393. doi: 10.1097/RLU.0000000000001554.
2017
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Manfredi M; Airoldi M; Tucci M; Buttigliero C; Parente A; Angusti T;
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. in Cancer treatment reviews / Cancer Treat Rev. 2017 Mar;54:1-9. doi: 10.1016/j.ctrv.2017.01.002. Epub 2017 Jan 11.
2017
AOU San Luigi di Orbassano
Buttigliero C; Tucci M; Vignani F; Scagliotti GV; Di Maio M;
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2017 Aug;69(4):349-358. doi: 10.23736/S0393-2249.16.02746-6. Epub 2016 Dec 22.
2017
AOU San Luigi di Orbassano
Bertaglia V; Tucci M; Vignani F; Buttigliero C; Aroasio E; Berruti A; Scagliotti GV; DI Maio M;
Zoledronic Acid Dosing Interval for Metastatic Cancer. in JAMA / JAMA. 2017 Apr 11;317(14):1477-1478. doi: 10.1001/jama.2017.2562.
2017
AOU San Luigi di Orbassano
Tucci M; Buttigliero C; Di Maio M;
Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias? in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2017 Apr 10;35(11):1264. doi: 10.1200/JCO.2016.69.3580. Epub 2017 Feb 6.
2017
AOU San Luigi di Orbassano
Buttigliero C; Tucci M; Vignani F; Di Maio M;
Cost of illness of urothelial bladder cancer in Italy. in ClinicoEconomics and outcomes research : CEOR / Clinicoecon Outcomes Res. 2017 Jul 24;9:433-442. doi: 10.2147/CEOR.S135065. eCollection 2017.
2017
AOU San Luigi di Orbassano
Gerace C; Montorsi F; Tambaro R; Cartenì G; De Luca S; Tucci M; Martorana G; Basso U; Cardosi L; Teruzzi C;
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. in BioMed research international / Biomed Res Int. 2017;2017:5618174. doi: 10.1155/2017/5618174. Epub 2017 Jun 7.
2017
AOU San Luigi di Orbassano
AO Ordine Mauriziano
Di Maio M; Scagliotti GV; Pignataro D; Vignani F; Buttigliero C; Leone G; Tucci M; Zichi C;
CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology
2017
AO Ordine Mauriziano
ASL Cuneo 2
AOU San Luigi di Orbassano
Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Cosmai L; Vignani F; Prati G; Scagliarini S; Berselli A; Pinto C; Baldari S; Annibale V; Lastoria S; Tucci M; Borsatti E; Monari F; Paganelli G; Verri E; Muto P; Panareo S; Mosca A; Storto G; et alii...
Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Rossetti S; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini PF; Damiani A; Procopio G; De Lisi D; Ruatta F; Scagliarini S; Donini M; Sperduti I; Basso U;
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castrationresistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Final results from a multicenter Italian study in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Biasco E; Fratino L; Facchini G; Iacovelli R; Re GL; Scagnoli S; Morelli F; D'Angelo A; Verderame F; Campadelli E; Ricotta R; Napolitano M; Sartori D; Borsellino N; Sperduti I; Maruzzo M;
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Facchini G; Iacovelli R; Mucciarini C; Zucali PA; Vicario G; Carrozza F; Sirotova Z; Messina C; Bordonaro R; La Torre L; Sacco C; Veccia A; Sperduti I; Zagonel V;
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Facchini G; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini P; Damiani A; Procopio G; De Lisi D; Ortega C; Scagliarini S; Donini M; Sperduti I; Basso U;
Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Biasco E; Fratino L; Rossetti S; Iacovelli R; Morelli F; D'Angelo A; Campadelli E; Verderame F; Borsellino N; Sartori D; Guida A; Ricotta R; Barni S; Maines F; Sperduti I; Zagonel V;
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)-based third-line treatment: Final results from a multicenter Italian study in Journal of Clinical Oncology
2017
AOU San Luigi di Orbassano
Caffo O; Bria E; De Giorgi U; Tucci M; Galli L; Fratino L; Rossetti S; Iacovelli R; Re GL; Mosillo C; Gasparro D; Guglielmini P; Damiani A; Procopio G; De Lisi D; Ortega C; Scagliarini S; Donini M; Sperduti I; Basso U;
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. in The Lancet. Oncology / Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
2016
AOU San Luigi di Orbassano
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Androgen deprivation modulates gene expression profile along prostate cancer progression. in Human pathology / Hum Pathol. 2016 Oct;56:81-8. doi: 10.1016/j.humpath.2016.06.004. Epub 2016 Jun 21.
2016
AOU San Luigi di Orbassano
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I;
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. in Cancer treatment reviews / Cancer Treat Rev. 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Epub 2016 Feb 12.
2016
AOU San Luigi di Orbassano
Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M;
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.
2016
AOU San Luigi di Orbassano
ASL Torino 5
Santini D; Messina C; Perin A; Lodde M; Fratino L; Berruti A; Mucciarini C; Nicodemo M; Bonetti A; Alesini D; Zucali PA; Vicario G; Massari F; Lo Re G; Donini M; Bortolus R; Spizzo G; D'Angelo A; Zagonel V; Procopio G; Mattioli R; Mansueto G; Facchini G; Aieta M; Scognamiglio F; Ortega C; Di Lorenzo G; Caffo O; De Giorgi U; et alii...
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. in European urology / Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28.
2016
AOU San Luigi di Orbassano
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M;
Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes in Journal of Clinical Oncology
2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Maines F; De Giorgi U; Facchini G; Fratino L; Gasparro D; Alesini D; Basso U; Tucci M; Ortega C; Scagliarini S; Verderame F; Barni S; D'Angelo A; Vicario G; Donini M; Carrozza F; Sava T; Sirotova Z; Santini D; Caffo O;
2016
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Veccia A; De Giorgi U; Facchini G; Fratino L; Gasparro D; Alesini D; Basso U; Tucci M; Ortega C; Scagliarini S; Verderame F; Lo Re G; Procopio G; Sabbatini R; Campadelli E; Zucali PA; Morelli F; Sartori D; Conteduca V; Caffo O;
Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP) in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Saad F; Keizman D; O'Sullivan JM; Carles J; Wirth M; Gillessen S; Thellenberg-Karlsson C; Miller K; Tucci M; Paganelli G; Procopio G; Gratt J; Seger M; Nilsson S; Heinrich D;
PRO-BMI study: Prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Tucci M; Lutrino SE; Di Maio M; Procopio G; Massari F; Calvani N; Fontanella C; Atzori F; Barni S; Caliolo C; Vignani F; Accettura C; Quaranta A; Mazzoni E; D'amico M; Scavelli C; Chetrì MC; Ferrara P; Cinieri S;
Effect of radium 223 on remission of bone metastases in androgen receptor-positive (AR+) salivary duct carcinoma (SDC) of the parotid in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Airoldi M; Pedani F; Bellini E; Contu V; Tucci M; Podio V; Raimondo L; Garzaro M;
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Caffo O; De Giorgi U; Alesini D; Fratino L; Ortega C; Tucci M; Scagliarini S; Zagonel V; Zucali PA; Morelli F; Sartori D; Sabbatini R; D'Angelo A; Donini M; Barni S; Procopio G; Sirotova Z; Sava T; Conteduca V; Galligioni E;
Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study in Journal of Clinical Oncology
2016
AOU San Luigi di Orbassano
Caffo O; De Giorgi U; Ferrau F; Donini M; Facchini G; Maruzzo M; Tucci M; Conteduca V; Maines F; Rossi L; Veccia A; Galligioni E;
2016
AOU San Luigi di Orbassano
Mottaghy F; Saad F; Galceran JC; Gillessen S; Heinrich D; Gratt J; Miller K; Nilsson S; O'Sullivan J; Tucci M; Wirth M; Heidenreich A;
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome. in Endocrine / Endocrine. 2015 Sep;50(1):223-30. doi: 10.1007/s12020-015-0525-x. Epub 2015 Jan 15.
2015
AOU San Luigi di Orbassano
Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A;
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. in Oncotarget / Oncotarget. 2015 May 20;6(14):12520-8. doi: 10.18632/oncotarget.3724.
2015
AOU San Luigi di Orbassano
Iuliani M; Pantano F; Buttigliero C; Fioramonti M; Bertaglia V; Vincenzi B; Zoccoli A; Ribelli G; Tucci M; Vignani F; Berruti A; Scagliotti GV; Tonini G; Santini D;
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. in Urologic oncology / Urol Oncol. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016. Epub 2015 Apr 20.
2015
AOU San Luigi di Orbassano
Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; et alii...
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. in European urology / Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.
2015
AOU San Luigi di Orbassano
Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; et alii...
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. in Cancer treatment reviews / Cancer Treat Rev. 2015 Dec;41(10):884-92. doi: 10.1016/j.ctrv.2015.08.002. Epub 2015 Aug 31.
2015
AOU San Luigi di Orbassano
Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV;
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. in European journal of pain (London, England) / Eur J Pain. 2015 Aug;19(7):881-8. doi: 10.1002/ejp.612. Epub 2014 Nov 5.
2015
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Sperlinga R; Campagna S; Berruti A; Laciura P; Ginosa I; Paoletti S; Giuliano PL; Tucci M; Rosato R; Scagliotti GV; Saini A;
Metastatic castration-resistant prostate cancer: time for innovation. in Future oncology (London, England) / Future Oncol. 2015;11(1):91-106. doi: 10.2217/fon.14.145.
2015
AOU San Luigi di Orbassano
Tucci M; Scagliotti GV; Vignani F;
Association between levels of hormones implied in steroid biosynthesis pathway and activity of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): An exploratory analysis in Journal of Clinical Oncology
2015
AOU San Luigi di Orbassano
Tucci M; Vignani F; Bertaglia V; Buttigliero C; Berruti A; Scagliotti GV; Di Maio M;
Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy in European Urology, Supplements
2015
AOU San Luigi di Orbassano
Castellano D; Bracarda S; Tucci M; Capoun O; Matveev V; Bodoky G; Fountzilas G; Kacso G; Borre M; Skoneczna I; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Molina A; Sternberg CN;
Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy after docetaxel (DOC): Preliminary results from a multicenter Italian study in Journal of Clinical Oncology
2015
AOU San Luigi di Orbassano
Caffo O; De Giorgi U; Facchini G; Fratino L; Gasparro D; Basso U; Alesini D; Tucci M; Ortega C; Verderame F; Procopio G; Lo Re G; Campadelli E; Omarini C; Donini M; Morelli F; Zucali PA; Sartori D; Conteduca V; Galligioni E;
Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience in Journal of Clinical Oncology
2014
AOU San Luigi di Orbassano
Caffo O; Basso U; Facchini G; Gasparro D; Alesini D; Tucci M; Ortega C; Fratino L; Campadelli E; Lo Re G; Sabbatini R; Procopio G; Zucali PA; D'Angelo A; Donini M; Massari F; Ratta R; Sava T; Messina C; De Giorgi U;
Circadian variation of breakthrough pain in cancer patients. in European journal of pain (London, England) / Eur J Pain. 2013 Feb;17(2):264-70. doi: 10.1002/j.1532-2149.2012.00184.x. Epub 2012 Jun 19.
2013
AOU San Luigi di Orbassano
ASL Cuneo 1
Saini A; Tucci M; Tampellini M; Maina D; Bouraouia K; Giuliano PL; Termine A; Castellano M; Campagna S; Laciura P; Berruti A;
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. in Cancer treatment reviews / Cancer Treat Rev. 2013 Dec;39(8):966-73. doi: 10.1016/j.ctrv.2013.03.003. Epub 2013 Apr 10.
2013
AOU San Luigi di Orbassano
Pia A; Vignani F; Attard G; Tucci M; Bironzo P; Scagliotti G; Arlt W; Terzolo M; Berruti A;
Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. in Open access journal of urology / Open Access J Urol. 2010 Jul 23;2:109-24. doi: 10.2147/rru.s6573.
2010
AOU San Luigi di Orbassano
Berruti A; Vignani F; Russo L; Bertaglia V; Tullio M; Tucci M; Poggio M; Dogliotti L;
Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2009;12(1):94-9. doi: 10.1038/pcan.2008.10. Epub 2008 Mar 11.
2009
AOU San Luigi di Orbassano
Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A;
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases in British Journal of Cancer
2008
AOU San Luigi di Orbassano
Generali D; Dovio A; Tampellini M; Tucci M; Tedoldi S; Torta M; Bonardi S; Allevi G; Aguggini S; Milani M; Harris AL; Bottini A; Dogliotti L; Angeli A; Berruti A;
Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. in The Journal of urology / J Urol. 2007 Sep;178(3 Pt 1):838-43; quiz 1129. doi: 10.1016/j.juro.2007.05.018. Epub 2007 Jul 16.
2007
AOU San Luigi di Orbassano
Berruti A; Mosca A; Porpiglia F; Bollito E; Tucci M; Vana F; Cracco C; Torta M; Russo L; Cappia S; Saini A; Angeli A; Papotti M; Scarpa RM; Dogliotti L;
Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. in British journal of cancer / Br J Cancer. 2005 Sep 19;93(6):633-8. doi: 10.1038/sj.bjc.6602767.
2005
AOU San Luigi di Orbassano
Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L;
Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up. in Urologic oncology / Urol Oncol. 2005 Jan-Feb;23(1):1-7. doi: 10.1016/j.urolonc.2004.06.003.
2005
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
Pharmacoeconomic comparison between chronochemotherapy and FOLFOX regimen in the treatment of patients with metastatic colorectal cancer: a cost-minimization study. in Tumori / Tumori. 2004 Jan-Feb;90(1):44-9.
2004
AOU San Luigi di Orbassano
Tampellini M; Bitossi R; Brizzi MP; Saini A; Tucci M; Alabiso I; Dogliotti L;
Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. in The International journal of biological markers / Int J Biol Markers. 2002 Oct-Dec;17(4):244-52. doi: 10.5301/jbm.2008.2194.
2002
AOU San Luigi di Orbassano
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A;
Background to and management of treatment-related bone loss in prostate cancer. in Drugs & aging / Drugs Aging. 2002;19(12):899-910. doi: 10.2165/00002512-200219120-00002.
2002
AOU San Luigi di Orbassano
Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L;
Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates in Journal of Urology
2001
AOU San Luigi di Orbassano
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Fontana D; Angeli A;
Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. in Clinical chemistry / Clin Chem. 1999 Aug;45(8 Pt 1):1240-7.
1999
AOU San Luigi di Orbassano
Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A;